Conference Day Three

7:45 Networking Breakfast & Conference Registration Networking Breakfast & Conference Registration

8:30 Chairperson’s Opening Remarks Chairperson’s Opening Remarks

8:45 Panel: Revising Your Pitch By Integrating The Feedback From Potential Partners Steven Ertel, SVP Corporate Development, Acceleron Pharma Stephen Ireland, SVP Business Development, Transtech Pharma Inc. Al Altomari, President and CEO, Agile Therapeutics Samantha Truex, VP, Business Development , Biogen Inc. Even with a compelling, well-crafted pitch, entrepreneurs looking for partnership opportunities may need to make adjustments to move partnering discussions to the next level. This session will help biotech executives learn how to listen more closely to the feedback they receive from potential partners, scrutinize business decisions that need to be made in response to the feedback and develop a strategy for re-approaching potential partners with new information Steven Ertel SVP Corporate Development, Acceleron Pharma Mr. Ertel joined Acceleron in January 2006 to lead the business development, market development, and investor/public relations functions. Mr. Ertel began his career in venture capital at Oxford Bioscience Partners and subsequently worked at several leading biotechnology companies including Genentech and Biogen Idec where he led project teams of preclinical and clinical stage programs, ran a market [read more] Stephen Ireland SVP Business Development, Transtech Pharma Inc. Mr. Ireland received his Bachelor of Science degree from Brock University in 1986. He began his career in sales and marketing with BioRad Laboratories in 1986 based in Hong Kong servicing all of Southeast Asia. Mr. Ireland joined Nalge Corporation in 1990 as Director of Asian Operations where he held line-management responsibility for their business throughout Asia. In 1993, Mr. Ireland joined F.H [read more] Al Altomari President and CEO, Agile Therapeutics Al Altomari is the President and Chief Executive Officer of Agile Therapeutics and a member of the Company's Board of Directors. Prior to being named President and CEO, Mr. Altomari served as Agile's Executive Chairman in which capacity he closed a $45 million venture round in May 2010. Mr. Altomari has more than 28 years of experience in the pharmaceutical industry, with more than 20 years focuse [read more] Samantha Truex VP, Business Development , Biogen Inc. Samantha Truex is Vice President, Business Development at Biogen Idec. She has been with Biogen Idec since 2006 and is currently leading business development for Biogen Idecís hemophilia/hematology areas. Prior to this role, Samantha managed Biogen Idecís long-lasting Factor IX and Factor VIII programs and the associated alliance with Swedish Orphan Biovitrum. From 2006-2008, Samantha was responsi [read more]

9:45 Panel: Analyzing Recent Deal Activity Across Therapeutic Areas Jones W. Bryan, Ph.D., VP Business Development and Licensing, Supernus Pharmaceuticals George Farmer, Principal, Research Analyst, Life Sciences, Canaccord Genuity Inc. Jeffrey Wasserstein, SVP Business Development & Strategy, Nycomed US Bradley L. Campbell, SVP Business Operations & Development, Amicus Therapeutics Analyzing key trends in deal-making can help understand the strategic directions the industry is taking and inform future decisions. This session will review and analyze recent deals incorporating all forms of therapeutics, vaccines and drug delivery technologies in all therapeutic areas and panelists will make predications on how they see these trends playing out over the next year. Jones W. Bryan, Ph.D. VP Business Development and Licensing, Supernus Pharmaceuticals George Farmer Principal, Research Analyst, Life Sciences, Canaccord Genuity Inc. Jeffrey Wasserstein SVP Business Development & Strategy, Nycomed US Jeff Wasserstein is SVP of Business Development & Strategy for Nycomed in the United States. In this role he is responsible for business development, portfolio management and strategic development for the Company’s PharmaDerm and Fougera operations. Prior to joining Nycomed, Jeff was President of Promius Pharma, a fully integrated, branded specialty pharmaceutical company which he [read more] Bradley L. Campbell SVP Business Operations & Development, Amicus Therapeutics Mr. Campbell heads a number of departments at Amicus including Business Development, Program Management, Commercial Planning, Technical Operations and Patient Advocacy. In this role, he has led numerous in licensing and out licensing evaluations and transactions including most recently a $230 M strategic collaboration with GSK Rare Diseases completed in 2010. Mr. Campbell was previously with Genzy [read more]

10:00 Refreshment Break & Networking Opportunity Refreshment Break & Networking Opportunity

11:15 Panel: Adapting In The Era Of Translational Research Sanj Singh, President & CEO, Ade Therapeutics Mike Hoerres, Principal, Geisinger Ventures Translational research is often summarized by the phrases "benchto- bedside" and "bedside-to-community" research. However, the true definition remains loose and proves to be a stumbling block for industry strategists interested in exploring this approach to product development. This session will cover opportunities and obstacles in translational research including operational changes in biotech, pharma and academia, funding opportunities and regulatory and commercial implications. Sanj Singh President & CEO, Ade Therapeutics Sanj Singh is Co-Founder, President and CEO of Ade Therapeutics. Sanj has led the development of the company since inception and brought products into the clinic, established key strategic alliances and partnerships to advance the product portfolio. Ade Therapeutics is a privately held market driven clinical-stage product development company located in Canada. The company’s vision is to be the wor [read more] Mike Hoerres Principal, Geisinger Ventures Mike Hoerres is Principal at Geisinger Ventures, the strategic venture group affiliated with Geisinger Health Systems (GHS). GHS is a non-for-profit, fully integrated health delivery system serving communities across much of Pennsylvania, and is a leading healthcare organization in the US. In his role at Geisinger Mr. Hoerres leads partnering efforts with the pharmaceutical and life science indust [read more]

11:45 Case Study: Reata Pharmaceuticals And Abbott Laboratories Collaborate To Develop AIMs Casi DeYoung, VP of Business Development, Reata Pharmaceuticals This case study will discuss the novel deal structure between Reata Pharmaceuticals, of Dallas, Texas and Abbott Laboratories to develop and commercialize bardoxolone methyl, Reata’ most advanced product in its platform of antioxidant inflammation modulators (AIMs). Key topics will include unique alignment of territories and responsibilities, plus strategies for maintaining nimbleness, responsiveness and flexibility of the small company, while leveraging world class global capabilities of large pharma Casi DeYoung VP of Business Development, Reata Pharmaceuticals Ms. DeYoung's previous roles have included business development, portfolio management, commercial operations and management consulting in biotech pharmaceutical companies in the US and abroad. Prior to Reata, she served as Vice President, Business Development for ODC Therapy. She also held U.S. and global positions at EMD Pharmaceuticals, the U.S. subsidiary of Germany-based Merck KGaA. Ms. DeYoun [read more]

12:45 Networking Lunch Networking Lunch

1:45 End Of BioNetwork East 2012 End Of BioNetwork East 2012